Publikationen in Zusammenarbeit mit Forschern von Massachusetts General Hospital (9)

2023

  1. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  2. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

    Breast Cancer Research and Treatment, Vol. 201, Núm. 1, pp. 43-56

  3. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 6, pp. 372-389

2022

  1. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. Genomic alterations in breast cancer: Level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

    Annals of Oncology, Vol. 30, Núm. 3, pp. 365-373

2017

  1. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544

2015

  1. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Nature Genetics, Vol. 47, Núm. 3, pp. 250-256

2012

  1. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis

    Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137